10x Genomics, Inc. balance sheet TXG

Annual Quarterly

As of Jun 30, 2026, 10x Genomics, Inc. had total assets of $1.0 billion and total liabilities of $204.5 million. Total assets were up 5.1% from a year earlier. Stockholders' equity was $825.5 million. It held $552.0 million in cash and investments against $78.8 million of total debt, net cash of $473.2 million. The current ratio, current assets divided by current liabilities, was 5.69.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019
Assets
Cash	503 +26.4%	474 +37.8%	344 -4.2%	359 +58.0%	227 -61.9%	596 -13.4%	689 +44.5%	476
Short-term investments	50 -0.1%	49 +0.2%	49 +67.7%	29 -86.0%	210	—	—	—
Cash and investments	552 +23.4%	523 +33.0%	393 +1.2%	389 -11.2%	438 -26.6%	596 -13.4%	689 +44.5%	476
Receivables	48 -4.9%	47 -46.5%	88 -23.5%	115 +10.2%	104 +22.2%	85 +66.5%	51 +53.5%	33
Inventory	53 -23.7%	56 -32.2%	83 +12.8%	74 -9.7%	82 +36.1%	60 +100.2%	30 +96.2%	15
Total current assets	675 +2.9%	684 +17.1%	584 -2.0%	596 -6.1%	635 -15.1%	748 -3.5%	774 +61.0%	481
Property and equipment, net	215 -10.2%	227 -10.3%	253 -9.6%	280 -3.4%	289 +70.7%	169 +132.7%	73 +49.2%	49
Goodwill	7 +53.4%	5 +0.0%	5 +0.0%	5 +0.0%	5 +0.0%	5	—	—
Total assets	1,030 +5.1%	1,041 +13.4%	919 -4.8%	965 -6.2%	1,029 +1.0%	1,019 +9.6%	929 +53.4%	606
Liabilities and equity
Accounts payable	21 +29.8%	13 -1.4%	13 -18.0%	16 -27.1%	22 +24.5%	17 +268.5%	5 -63.9%	13
Total current liabilities	119 +5.6%	153 +30.5%	118 -7.5%	127 -2.9%	131 +18.7%	110 -6.6%	118 +87.4%	63
Total liabilities	205 -1.1%	245 +17.5%	209 -7.0%	224 +0.4%	223 +10.9%	201 +5.8%	190 +2.4%	186
Stockholders' equity	826 +6.8%	796 +12.1%	710 -4.2%	741 -8.0%	806 -1.4%	818 +10.6%	739 +75.9%	420
Debt
Debt due within a year	—	—	—	—	—	—	—	10
Long-term debt	—	—	—	—	—	—	0 -100.0%	20
Lease liabilities	79 -9.2%	84 +2.1%	83 -13.4%	95 +0.2%	95 +16.1%	82 +30.2%	63	—
Total debt	79 -9.2%	84 +2.1%	83 -13.4%	95 +0.2%	95 +16.1%	82 +30.2%	63 +111.9%	30
Net cash	473 +31.3%	439 +41.3%	311 +6.0%	293 -14.3%	342 -33.4%	514 -17.8%	626 +40.0%	447
Ratios
Current ratio	5.69x	4.46x	4.97x	4.69x	4.85x	6.77x	6.56x	7.63x
Debt to equity	0.10x	0.11x	0.12x	0.13x	0.12x	0.10x	0.09x	0.07x
Return on equity	-9.10%	-5.47%	-25.72%	-34.42%	-20.60%	-7.12%	-73.43%	-7.44%
Return on assets	-7.29%	-4.18%	-19.88%	-26.43%	-16.13%	-5.71%	-58.40%	-5.16%
Book value per share	—	6.24	5.81	6.22	6.99	7.27	6.81	4.36

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Laboratory Analytical Instruments (SIC 3826)
Listed as: TXG (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Pleasanton, CA
SEC filer status: Large accelerated filer
SEC CIK: 1770787

Other Laboratory Analytical Instruments companies

All 25 Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.